DPP4 and Miyoshi myopathy: We further explored whether pretreatment with conventional therapy (dexamethasone: Daexa) or novel agents (bortezomib: BTZ, lenalidomide: Lena) facilitates huCD26mAb-induced ADCC against CD26+ MM cells.